Ideal Implant Inc is planning to sell its IDEAL IMPLANTĀ® to Valeant Pharmaceuticals, subject to pending federal Food and Drug Administraton (FDA) approval of the novel, hybrid breast implant.

As part of the deal, Ideal Implant Inc will receive a purchase price based on revenue in sales within a 3-year span. The transaction, which is reported to close in a matter of days, is subject to completion of its final phase in nationwide clinical trials with FDA approval.

Sources say FDA approval of the IDEAL implant is “imminent.”

The IDEAL IMPLANTĀ® is a patent-protected, saline-filled breast implant designed to contour the chest wall and feel similar to a silicone gel implant. This best-of-both-worlds device was developed by Dallas plastic surgeon Robert Hamas, MD.

[Source: PRWeb]